---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011233"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:47:31.438050+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# InspireMD's C-GUARDIANS 12-month abstract accepted for LINC 2024; prior 30-day DSMI 0.95%

## Summary
- Abstract of 12-month outcomes from C-GUARDIANS trial (316 patients, 24 sites) accepted for LINC 2024 (May 28-31, Leipzig).
- Previously reported 30-day DSMI rate of 0.95% (ITT) and 0.63% (per-protocol).
- Positive 12-month data could support PMA submission later in 2024 and potential U.S. launch of CGuard Prime in H1 2025.
- Trial evaluates CGuard Carotid Stent System for carotid artery stenosis; primary endpoint includes death, stroke, MI through 365 days.

## SEC filing metadata
- accession: 0001493152-24-011233
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315224011233/0001493152-24-011233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315224011233/from8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011233
- JSON: https://secwatch.observer/filing/0001493152-24-011233.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011233.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.